§Appl. No. 09/890,654 Amdt. dated August 10, 2005 Reply to Office Action February 10, 2005

Listing of Claims:

Please amend the claims as follows:

Claim 1 (Cancelled)

Claim 2 (Cancelled)

Claim 3 (Cancelled)

Claim 4 (Cancelled)

Claim 5 (Cancelled)

Claim 6 (Cancelled)

Claim 7 (Cancelled)

Claim 8 (Cancelled)

Claim 9 (Previously Presented) A single test kit package for determining the concentration of thrombin inhibitors in a non-turbid body liquid or a non-turbid extract from a body liquid, comprising the following components: K1) a solution of a coagulation-inhibiting substance not interfering in the transformation of prothrombin into active meizothrombin or meizothrombin-des fragment 1; K2) a chromogenic or fluorogenic substrate dissociable by active meizothrombin or meizothrombin-des fragment 1; K3) a solution of a substance dissociating prothrombin into meizothrombin or meizothrombin-des fragment 1; and K4) a standard curve for determining the amount of thrombin inhibitor in a sample.

Claim 10 (Previously Presented) A single test kit package for determining the activity of thrombin inhibitors in a non-turbid body or in a non-turbid extract from a body liquid or in a non-turbid non-natural aqueous liquid, comprising the following kit components: K1) a chromogenic or fluorogenic substrate dissociable by active meizothrombin or meizothrombin-des fragment 1

3

ALBRE-0017

§Appl. No. 09/890,654 Amdt. dated August 10, 2005 Reply to Office Action February 10, 2005

and; K2) a solution of a substrate dissociating prothrombin into meizothrombin or meizothrombin-des fragment 1; or meizothrombin or meizothrombin-des fragment 1; and K3) a standard curve for determining the amount of thrombin inhibitor in a sample.

Claim 11 (Cancelled)

Claim 12 (Previously Presented) A test kit according to claim 9, further comprising a solution with prothrombin is provided.

Claim 13 (Cancelled)

Claim 14 (Cancelled)

Claim 15 (Previously Presented) A kit package of claim 9, further comprising meizothrombin or meizothrombin-des fragment 1.

Claim 16 (Cancelled)

Claim 17 (Previously Presented) A single test kit package for determining the concentration of thrombin inhibitors I a non-turbid body liquid or a non-turbid extract from a body liquid, comprising the following components: K1) a solution of a coagulation-inhibiting substance not interfering in the transformation of prothrombin into active meizothrombin or meizothrombin-des fragment 1; K2) a chromogenic or fluorogenic substrate dissociable by active meizothrombin or meizothrombin-des fragment 1; K3) a solution comprising meizothrombin or meizothrombin-des fragment 1; and K4) a standard curve for determining the amount of a thrombin inhibitor in a sample.

4

ALBRE-0017

§Appl. No. 09/890,654 Amdt. dated August 10, 2005 Reply to Office Action February 10, 2005

Claim 18 (Cancelled)

Claim 19 (Previously Presented) A single test kit package for determining the concentration of thrombin inhibitors in a non-turbid body liquid or a non-turbid extract from a body liquid, comprising the following components: K1) a solution of a coagulation-inhibiting substance not interfering in the transformation of prothrombin into active meizothrombin or meizothrombin-des fragment 1; K2) a chromogenic or fluorogenic substrate dissociable by active meizothrombin or meizothrombin-des fragment 1; K3) a solution of a substance dissociating prothrombin into meizothrombin or meizothrombin-des fragment 1; K4) a known amount of hirudin for determining a standard curve.

Claim 20 (New) A single test kit package of claim 9, wherein said coagulation-inhibiting substance is a fibrin polymerization inhibiting substance.

Claim 21 (New) A single test kit package of claim 20, wherein the fibrin polymerization inhibiting substance is a Gly-Pro-Arg-Pro tetrapeptide.

Claim 22 (New) A single test kit package of claim 10, wherein said coagulation-inhibiting substance is a fibrin polymerization inhibiting substance.

Claim 23 (New) A single test kit package of claim 22, wherein the fibrin polymerization inhibiting substance is a Gly-Pro-Arg-Pro tetrapeptide.

5 ALBRE-0017